Genzyme ( Genzyme)

Primary tabs

Genzyme's picture

Management

Contact Address

About Genzyme

Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world’s third-largest biotechnology company which employed more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products in the market. In 2006 and 2007, Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.

Genzyme press release, blog etc

Thu, 02/07/2019 - 00:13 Sanofi announces additional data on avalglucosidase alfa in Pompe disease
Mon, 02/04/2019 - 22:46 Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
Wed, 01/30/2019 - 00:25 Sanofi Presents Research Advances in Rare Genetic Diseases at 15th Annual WORLDSymposium 2019
Wed, 01/09/2019 - 15:01 New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder
Thu, 11/29/2018 - 06:57 Sanofi builds focus on rare blood disorders and cancers
Tue, 11/06/2018 - 11:32 FDA grants priority review for Dupixent (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Fri, 10/19/2018 - 10:01 Kevzara (sarilumab) data at the 2018 ACR/ARHP Annual Meeting provide additional insight on safety, efficacy in rheumatoid arthritis
Thu, 10/18/2018 - 22:57 FDA approves asthma indication for Dupixent (dupilumab)
Tue, 10/16/2018 - 06:24 Dupixent (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Wed, 10/10/2018 - 18:35 Sanofi Presents 8-Year Data on Lemtrada (Alemtuzumab)
Wed, 10/10/2018 - 17:57 Sanofi presents new data on Aubagio (teriflunomide)
Sun, 10/07/2018 - 21:17 More Than 30 Data Presentations from Sanofi Genzymes Multiple Sclerosis Franchise to Be Featured at the 34th ECTRIMS Congress
Sun, 10/07/2018 - 20:06 Libtayo (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Fri, 09/28/2018 - 06:43 FDA approves Libtayo (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sat, 09/15/2018 - 11:51 Positive Phase 3 results presented for Dupixent (dupilumab) show significant improvement on multiple measures of disease severity in adolescents with moderate-to-severe atopic dermatitis
Mon, 09/03/2018 - 10:21 Cablivi (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Wed, 07/18/2018 - 17:58 Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
Mon, 06/04/2018 - 13:10 New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma